The IMpower150 clinical trial conducted on non-squamous non-small cell lung cancer demonstrated that the combination of atezolizumab plus bevacizumab (anti-VEGF antibody) and chemotherapy markedly prolonged the progression-free and overall survival of patients with metastatic non-squamous non-small cell lung cancer (5). The gene discussed is VEGFA; the disease is non-small cell squamous lung carcinoma.